Charles River Laboratories (CRL) financial statements
+210.0%since 2008
- FY2025 revenue
- $4.0B▼ −0.9%
- FY2025 net income
- −$144M▼ −750.1%
- FY2025 diluted EPS
- −$2.91▼ −1,555.0%
- FY2025 free cash flow
- $518M▲ +3.4%
Charles River Laboratories income statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 27 Dec 2025 | 28 Dec 2024 | 30 Dec 2023 |
| Revenue | 4,015 | 4,050 | 4,129 |
| Operating income | 25 | 227 | 617 |
| Pretax income | -100 | 93 | 581 |
| Net income | -144 | 22 | 475 |
| Diluted earnings per share | -2.91 | 0.20 | 9.22 |
Charles River Laboratories balance sheet
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 27 Dec 2025 | 28 Dec 2024 | 30 Dec 2023 |
| Cash and cash equivalents | 214 | 206 | 284 |
| Total assets | 7,135 | 7,528 | 8,195 |
| Total liabilities | 3,924 | 4,020 | 4,536 |
| Total equity | 3,170 | 3,467 | 3,602 |
| Long-term debt | 2,136 | 2,240 | 2,647 |
Charles River Laboratories cash flow statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 27 Dec 2025 | 28 Dec 2024 | 30 Dec 2023 |
| Operating cash flow | 738 | 735 | 684 |
| Capital expenditure | -219 | -233 | -319 |
| Free cash flow (derived) | 518 | 502 | 365 |
| Share repurchases | -361 | -119 | -24 |
Quarterly highlights
| USD millions | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 |
|---|---|---|---|---|
| Period ended | 26 Sep 2026 | 27 Jun 2026 | 28 Mar 2026 | 27 Dec 2025 |
| Revenue (derived) | 983 | 1,004 | 996 | 994 |
| Operating income (derived) | 203 | 120 | 120 | -283 |
| Net income (derived) | 333 | -1 | -15 | -277 |
| Diluted earnings per share | 6.86 | -0.03 | -0.30 | n/a |
| Operating cash flow (derived) | 254 | 180 | 41 | 148 |
| Total assets | 7,452 | 7,532 | 7,730 | 7,135 |
Charles River Laboratories major shareholders
| Holder | Share of class | Shares | Filed |
|---|---|---|---|
| Abigail P. Johnson | 12.4% | 5,922,755 | 5 November 2026 |
| FMR LLC | 12.4% | 5,922,755 | 5 November 2026 |
| Vanguard Capital Management | 7.4% | 3,634,376 | 30 April 2026 |
| BlackRock, Inc. | 6.9% | 3,524,401 | 17 April 2025 |
| T. Rowe Price Associates, Inc. | 6.3% | 3,010,619 | 16 November 2026 |
Charles River Laboratories 10-K and SEC filings
| Filed | Form | Type | Description |
|---|---|---|---|
| 9 November 2026 | 8-K | Current report | FORM 8-K |
| 4 November 2026 | 10-Q | Quarterly report | Quarterly report |
| 4 November 2026 | 8-K | Current report | Current report |
| 24 September 2026 | 8-K | Current report | Current report |
| 5 August 2026 | 10-Q | Quarterly report | Quarterly report |
| 5 August 2026 | 8-K | Current report | Current report |
| 11 May 2026 | 8-K | Current report | FORM 8-K |
| 7 May 2026 | 10-Q | Quarterly report | Quarterly report |
Common questions
What was Charles River Laboratories' revenue in fiscal 2025?
Charles River Laboratories reported $4.0 billion in revenue for fiscal 2025, the year ended 27 December 2025, down 0.9% from fiscal 2024.
What was Charles River Laboratories' net income in fiscal 2025?
Charles River Laboratories reported a net loss of $144 million for fiscal 2025, the year ended 27 December 2025. Diluted earnings per share were −$2.91.
What was Charles River Laboratories' free cash flow in fiscal 2025?
Charles River Laboratories had $518 million in free cash flow in fiscal 2025. Operating cash flow was $738 million and capital expenditure was $219 million.
What were Charles River Laboratories' total assets at the end of fiscal 2025?
Charles River Laboratories reported total assets of $7.1 billion at the end of fiscal 2025, the year ended 27 December 2025.
How much Charles River Laboratories history do I get?
Every account gets the full history, annual and quarterly, with first reported values and as of dates.
Start with a free key
Free $10 credits every month, no card.Free $10 credits a month, no card.